ArticleDrug delivery and translational research2025
CEB-01 membrane loaded with SN-38 for local post-resection control and metastasis reduction in preclinical pancreatic cancer models.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is an aggressive malignancy with extremely poor prognosis, in which resection surgery remains the only therapeutic option with curative intent. Patients often present with locoregional metastases in lymph nodes, peritoneum and liver at diagnosis (~ 50-60% of patients), precluding the possibility of surgical resection. In addition, majority of patients develop tumor recurrence after surgery, which can be local or metastatic, in both cases negatively affecting survival outcomes. Irinotecan has proven effective as an adjuvant setting after surgery and currently used in chemotherapeutic combination regimes for the management of PC. The extreme low solubility of irinotecan's active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), along with its instability at physiological pH, creates significant challenges for SN-38 systemic administration as a free drug, despite its much greater potency compared to irinotecan. CEB-01 is a novel formulation of SN-38 in the form of a biodegradable nanofiber Poly (Lactic-co-Glycolic Acid) (PLGA) membrane. Implanted in the PC surgical bed, CEB-01 releases SN-38 in a prolonged manner for tumor growth control.Using in vivo pancreatic models, CEB-01 shows statistically significant reduction of postoperative tumor growth at local concentrations of SN-38 between 25 and 50 µg/cm
Indexed as
Identifiers
41225246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.